Table 1 Clinical and pathologic features of a series of 459 invasive lobular carcinomas (ILC).
Patients | Patients (%) | |
|---|---|---|
Number of cases | 459 | 100 |
Age | ||
<50 years | 90 | 19.6 |
≥50 years | 369 | 80.4 |
Menopausal status | ||
Premenopausal | 95 | 22.3 |
Postmenopausal | 330 | 77.7 |
Missing | 34 | |
Unifocality | ||
No | 73 | 16.2 |
Yes | 378 | 83.8 |
Missing | 8 | |
ILC histological type | ||
Classic | 312 | 68.0 |
Mixed | 119 | 25.9 |
Alveolar | 17 | 3.7 |
Solid | 11 | 2.4 |
Grade | ||
G1 | 45 | 9.8 |
G2 | 366 | 79.7 |
G3 | 48 | 10.5 |
Tumor size | ||
pT1 | 309 | 67.3 |
pT2 | 112 | 24.4 |
pT3 | 38 | 8.3 |
Lymph node metastases | ||
pN0 | 340 | 74.1 |
pN1 | 78 | 17.0 |
pN2 | 24 | 5.2 |
pN3 | 13 | 2.8 |
pNx | 4 | 0.9 |
Multinucleation | ||
No | 338 | 73.6 |
Yes | 121 | 26.4 |
Prominent nucleoli | ||
No | 338 | 74.4 |
Yes | 116 | 25.6 |
Missing | 5 | |
Nottingham Prognostic Index | ||
Excellent | 33 | 7.3 |
Good | 216 | 47.5 |
Moderate | 174 | 38.2 |
Poor | 32 | 7.0 |
Missing | 4 | |
Estrogen receptor | ||
No | 18 | 3.9 |
Yes | 441 | 96.1 |
Progesterone receptor | ||
No | 127 | 27.5 |
Yes | 332 | 72.5 |
HER2 amplification/overexpression | ||
No | 387 | 95.6 |
Yes | 18 | 4.4 |
Missing | 54 | |
Surgical treatment | ||
Lumpectomy | 321 | 69.9 |
Mastectomy | 138 | 30.1 |
Hormone therapy | ||
No | 93 | 20.3 |
Yes | 366 | 79.7 |
Adjuvant chemotherapy | ||
No | 359 | 78.2 |
Yes | 100 | 21.8 |
Radiotherapy | ||
No | 40 | 8.7 |
Yes | 419 | 91.3 |
Trastuzumab | ||
No | 446 | 97.2 |
Yes | 13 | 2.8 |
Local recurrences | ||
No | 437 | 95.2 |
Yes | 22 | 4.8 |
Lymph node metastases relapse | ||
No | 455 | 99.1 |
Yes | 4 | 0.9 |
Distant metastases | ||
No | 418 | 91.9 |
Yes | 41 | 8.9 |
Survival | ||
Alive | 422 | 91.9 |
Deceased | 37 | 8.1 |
